AdjuTec Pharma’s APC148 shines at ESCMID congress

At the recent ESCMID congress, organised by the European Society of Clinical Microbiology and Infectious Diseases, AdjuTec Pharma presented a poster highlighting the results of the phase I single ascending dose study for APC148, aimed at tackling antibiotic resistance. With more clinical trials on the horizon, AdjuTec is hopeful that APC148 will prove to be a powerful new tool against multidrug-resistant bacteria.

Read the article at biostock.se:

https://www.biostock.se/en/2025/04/adjutec-pharmas-apc148-shines-at-escmid-congress/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/